AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals
LONDON and PHOENIX, Ariz., June 06, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today announced the establishment of a joint clinical collaboration agreement with University Hospitals.
Per the terms of this agreement, University Hospitals will provide tissue samples with clinical outcomes to AccuStem for research purposes. The scope of the agreement covers a multitude of different cancers but will initially focus on breast cancer cases to support further validation of the StemPrintER test. The goal of the initial project is to build on the strong foundation of data for StemPrintER by demonstrating additional clinical utility beyond identifying patients’ risk of recurrence. This next step is critical for women with early stage breast cancer because there are many tests to determine the need for chemotherapy but there are no genomic tools to inform decisions earlier in the continuum of care. StemPrintER may be able to shift this paradigm by informing physicians of the most effective approaches to surgical or radiological treatment.
“AccuStem has arrived at an important juncture as we progress toward commercializing StemPrintER,” said Wendy Blosser, Chief Executive Officer of AccuStem. “With this collaboration, we intend to expand beyond identifying a patient’s prognosis by addressing unanswered clinical questions and supporting surgeons and radiation oncologists with their treatment planning.”
AccuStem and its clinical collaborators plan to present the data obtained under this agreement at scientific conferences and to publish the findings in peer-reviewed medical journals. Those activities will help to bolster the foundation of data for StemPrintER and familiarize physicians with its utility and value in clinical decision making with the ultimate goal of improving patient outcomes and quality of life.
“We are excited to work with AccuStem on this clinical project,” said Hannah Gilmore, Division Chief, Anatomic Pathology, University Hospitals Cleveland Medical Center and Professor of Pathology, Case Western Reserve University. “I am very interested in the foundation for the StemPrintER test and think that it could have important implications for treatment planning in breast cancer and perhaps many other tumor types.”
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness”, we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.
About University Hospitals / Cleveland, Ohio
Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 21 hospitals (including five joint ventures), more than 50 health centers and outpatient facilities, and over 200 physician offices in 16 counties throughout northern Ohio. The system’s flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Northeast Ohio Medical University, Oxford University, the Technion Israel Institute of Technology and National Taiwan University College of Medicine. The main campus also includes the UH Rainbow Babies & Children's Hospital, ranked among the top children’s hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, with more than 3,000 active clinical trials and research studies underway. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home to 19 Clinical Care Delivery and Research Institutes. UH is one of the largest employers in Northeast Ohio with more than 30,000 employees. Follow UH on LinkedIn, Facebook and Twitter. For more information, visit UHhospitals.org.
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. AccuStem Sciences, Inc. assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Standard Lithium Strengthens C-Suite: Salah Gamoudi Appointed CFO, Kara Norman Steps Into New Role as CAO25.9.2023 12:01:09 CEST | Press release
VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium company, today announced an enhanced C-suite with the addition of Salah Gamoudi as Chief Financial Officer, effective October 1, 2023. This decision aligns with the Company's efforts to bolster its senior leadership as it prepares for a dynamic phase of growth. Robert Mintak, CEO and Director of Standard Lithium, stated, “As we place greater emphasis on commercial construction, resource expansion, and strategic partnerships, Salah's addition is timely. Kara Norman's leadership as CFO, especially during our early growth and the NYSE American listing, has been foundational. With Salah joining as CFO and Kara transitioning to the Chief Accounting Officer role, we're strategically positioning our leadership for the Company's next chapter.” Salah Gamoudi commented, “Joining Standard Lithium at
Concentrix and Webhelp Complete Combination, Creating a Diversified Global CX Leader, Well-Positioned for Growth25.9.2023 12:00:00 CEST | Press release
NEWARK, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Concentrix Corporation (NASDAQ: CNXC), a leading global provider of customer experience (CX) services and technologies, today announced it has closed its combination with Webhelp and the integration of the two companies is underway. While the combined company finalizes its permanent name, it will operate under the trade name Concentrix + Webhelp. This combination further positions Concentrix + Webhelp as a global CX leader, with an expanded breadth of generative AI solutions, digital capabilities, and high-value services. It also strengthens its end-to-end CX value proposition, with one of the most robust, well-balanced global footprints in the industry to help the world’s best brands transform customer experiences and achieve their business goals. “I am excited to embark on this new journey together and believe that, with our combined strengths, we are uniquely positioned to redefine the industry and design, build and run the future o
eGain Launches AssistGPT™, First-of-Its-Kind Solution to Automate Knowledge for Customer Engagement25.9.2023 12:00:00 CEST | Press release
SUNNYVALE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- eGain Corporation (NASDAQ: EGAN), the leading knowledge management platform provider for customer engagement automation, launched eGain AssistGPT™ at its Solve™ 23 conference, being held on September 25, at the Brewery, London. An integral part of the eGain Knowledge Hub and powered by Generative AI out of the box, AssistGPT is a comprehensive zero-code solution for Knowledge Automation. For example, knowledge content draft creation, which used to take weeks, can now be completed in just a few minutes. The solution also helps customers in their omnichannel journeys with quick answers and contact center agents and business analysts in the flow of their work. An AI Console allows administrators to define guard rails for the use of generative AI, manage prompts, and orchestrate it with other AI technologies in the enterprise. AssistGPT comes with a best practice prompt library, which enables organizations to add business-specific promp
EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)25.9.2023 11:55:00 CEST | Press release
Media Release Subcutaneous EPKINLYTM(epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapyApproval based on results of EPCORETM NHL-3 and EPCORETM NHL-1 clinical trials, evaluating EPKINLYin patients with certain types of R/RLBCLLBCLis a common form of non-Hodgkin’s lymphoma (NHL) and currently has limited treatment options, particularly in the R/R setting COPENHAGEN, Denmark; September 25, 2023 – Genmab A/S (Nasdaq:GMAB) announcedtoday that the Japan Ministry of Health, Labour and Welfare has approved EPKINLYTM (epcoritamab) as the first and only T-cell engaging bispecific antibody treatment in Japan of adult patients with certain types of relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL)
Wolters Kluwer identifies ESG reporting challenges, demonstrates how technology brings clarity and competitive advantage25.9.2023 11:01:56 CEST | Press release
PRESS RELEASE Wolters Kluweridentifies ESG reporting challenges,demonstrates howtechnology brings clarity and competitive advantage Wolters Kluwer’s Corporate Performance and ESG divisionpoised to play leading role in enabling businesses to navigate emerging ESG reporting challenges LONDON – September 25, 2023– Wolters Kluwer’s Corporate Performance & ESG (CP & ESG) division has set out key issues major corporate and financial services institutions should consider when tackling emerging ESG reporting challenges. The insights are featured in a new white paper, “Bringing clarity to the complexity of financial and ESG reporting,” which zeroes in on the significant impact that the expected enforcement of global ESG regulations will have on multinational companies. The paper, authored by Wolters Kluwer CP & ESG experts, recommends that companies work quickly to leverage technology to bring clarity to the myriad of ESG expectations they face, by transforming the way they collect, report, ana